Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
salmeterol + fluticasone propionate (GSK)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
GW815SF is a fixed-dose combination therapy developed by GSK, consisting of the long-acting beta-2 adrenergic agonist (LABA) salmeterol and the inhaled corticosteroid (ICS) fluticasone propionate. Formulated as a hydrofluoroalkane (HFA) metered-dose inhaler (MDI), it is indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol provides sustained bronchodilation by stimulating beta-2 adrenergic receptors in the airway smooth muscle, while fluticasone propionate exerts potent anti-inflammatory effects by activating glucocorticoid receptors. This specific formulation was developed to provide a propellant-based alternative to dry powder inhalers (DPI), and its efficacy and safety have been extensively evaluated in both adult and pediatric populations.
- Brand names
- AdvairSeretideAdvair HFASeretide Evohaler
- Other names
- salmeterol xinafoate + fluticasone propionate
02
Targets
ADRB2 (β2)ADRB1 (β1)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on salmeterol + fluticasone propionate (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on salmeterol + fluticasone propionate (GSK).